Supplementary Financial Information (Unaudited) - Quarterly Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2018	[1]	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	[2]	Dec. 31, 2017	[3]	Sep. 30, 2017	[4]	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total revenue	$ 86,531		$ 78,009	$ 69,814	$ 60,136		$ 85,683		$ 84,511		$ 84,423	$ 93,584
Gross profit	49,526		43,462	39,611	32,546		53,084		42,071		47,835	53,513	$ 165,145	$ 196,503	$ 180,696
Net income (loss)	$ (21,631)		$ (22,665)	$ (28,464)	$ (22,991)		$ 102		$ (48,766)		$ (14,967)	$ (11,273)	$ (95,751)	$ (74,904)	$ 99,456
Basic earnings per share (in dollars per share)	$ (0.49)		$ (0.52)	$ (0.65)	$ (0.53)				$ (1.15)		$ (0.36)	$ (0.27)	$ (2.19)	$ (1.78)	$ 2.45
Diluted earnings per share (in dollars per share)	$ (0.49)		$ (0.52)	$ (0.65)	$ (0.53)				$ (1.15)		$ (0.36)	$ (0.27)	$ (2.19)	$ (1.78)	$ 2.25

[1] The Company recorded a charge of $7,000 due to impairment of a non-marketable equity investment.

[2] The benefit for income taxes included partial release of federal valuation allowance resulting from the transfer of an acquired in-process research and development to developed technology in 2018 which allowed the related deferred tax liability to be considered a source of income for realizing deferred tax assets, as well as the revaluation of the foreign deferred tax liability on the in-process research and development based on the foreign tax rates applicable to the anticipated reversal periods.

[3] The benefit for income taxes included revaluation of deferred tax liabilities to the new federal tax rate of 21% and tax benefit from intercompany transfer of intellectual property rights.

[4] The Company abandoned a project related to certain developed technology and in-process research and development from the ClariPhy acquisition which resulted to an impairment charge of $47,014.